A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- Histologic documentation of locally advanced, recurrent or metastatic incurable solid
malignancy that has progressed after all available standard therapy or for which
standard therapy has proven to be ineffective or intolerable, or is considered
inappropriate

- Confirmed availability of representative tumor specimens in paraffin blocks/unstained
slides

- Measurable disease per RECIST v1.1

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate hematologic and end organ function

- For female participants of childbearing potential, agreement to use highly effective
form(s) of contraception and to continue its use for 6 months after the last dose of
MOXR0916

Exclusion Criteria:

- Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy,
within 3 weeks prior to initiation of study treatment (hormonal therapy with
gonadotropin-releasing hormone agonists or antagonists for prostate cancer and
palliative radiotherapy greater than (>) 2 weeks prior to Cycle 1, Day 1 are allowed)

- Eligibility based on prior treatment with immunomodulatory agents depends on the
mechanistic class of the drug and the cohort for which the participant is being
considered

- Adverse events from prior anti-cancer therapy that have not resolved to Grade less
than or equal to ( replacement therapy

- Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases

- Leptomeningeal disease

- Malignancies other than disease under study within 5 years

- History of autoimmune disease

- History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
organizing pneumonia, or evidence of active pneumonitis on screening chest computed
tomography (CT) scan; history of radiation pneumonitis in the radiation field
(fibrosis) is permitted

- Positive test for human immunodeficiency virus infection

- Active hepatitis B or active hepatitis C

- Severe infections within 4 weeks or signs or symptoms of infection within 2 weeks
prior to Cycle 1

- Prior allogeneic bone marrow transplantation or prior solid organ transplantation

- Significant cardiovascular disease

- Known clinically significant liver disease